Provided by Tiger Trade Technology Pte. Ltd.

RAPT Therapeutics, Inc.

58.02
0.0000
Volume:- -
Turnover:645.21M
Market Cap:1.68B
PE:-4.98
High:58.02
Open:58.02
Low:58.02
Close:58.02
52wk High:58.02
52wk Low:5.67
Shares:28.96M
Float Shares:25.81M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.6600
EPS(LYR):-25.4880
ROE:-85.37%
ROA:-51.35%
PB:11.06
PE(LYR):-2.28

Loading ...

Dow Jones Top Company Headlines at 3 AM ET: GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments | Baidu's ...

Dow Jones
·
Jan 20

LIVE MARKETS-Before the bell: EU futures dip, French drink makers eyed

Reuters
·
Jan 20

UK Stocks-Factors to watch on January 20

Reuters
·
Jan 20

GSK to Buy RAPT Therapeutics in $2.2 Billion Deal for Promising Food Allergy Therapy

Reuters
·
Jan 20

RAPT Therapeutics (RAPT) Receives a Buy from Piper Sandler

TIPRANKS
·
Jan 16

TD Cowen Initiates Coverage on RAPT Therapeutics With Buy Rating

MT Newswires Live
·
Dec 18, 2025

RAPT Therapeutics Chief Medical Officer William Ho to Depart at Year-End

Reuters
·
Nov 29, 2025

J.P. Morgan Remains a Buy on RAPT Therapeutics (RAPT)

TIPRANKS
·
Nov 12, 2025

Rapt Therapeutics Unveils Pipeline Progress for Ozureprubart in Allergic Diseases

Reuters
·
Nov 11, 2025

RAPT Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

RAPT Therapeutics : Barclays Cuts Target Price to $56 From $58

THOMSON REUTERS
·
Nov 07, 2025

Rapt Therapeutics shares ‘exceptionally compelling,’ says Clear Street

TIPRANKS
·
Nov 07, 2025

Promising Clinical and Financial Developments Drive Buy Rating for RAPT Therapeutics

TIPRANKS
·
Nov 07, 2025

Buy Rating for RAPT Therapeutics Driven by Promising Ozureprubart Data and Strategic Growth Plans

TIPRANKS
·
Nov 07, 2025

RAPT Therapeutics Q3 EPS $(0.65) Beats $(0.80) Estimate

Benzinga
·
Nov 06, 2025

Rpt- RAPT Therapeutics Q3 EPS USD -0.65

THOMSON REUTERS
·
Nov 06, 2025

Rapt Therapeutics Q3 net loss narrows as R&D costs drop

Reuters
·
Nov 06, 2025

RAPT Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $72 From $27

THOMSON REUTERS
·
Oct 27, 2025

Clear Street positive on Rapt Therapeutics into food allergy study

TIPRANKS
·
Oct 27, 2025

Guggenheim Initiates RAPT Therapeutics at Buy With $70 Price Target

MT Newswires Live
·
Oct 27, 2025